Introduction
============

Advantages of blood pressure (BP) self-measurement have been well documented ([@b25]; [@b31]; [@b19]). Indeed, self-BP measurement (sBPm) not only provides valuable information for hypertension diagnosis but also on BP control of the treated patient, and it improves patient's compliance with antihypertensive therapy ([@b14]). Therefore, it is appropriate to encourage the widespread use of self-recorded BP as an important adjunct to the clinical care of some patients with hypertension ([@b28]; [@b2]). Clinical indications of sBPm have been recently highlighted in several international scientific society recommendations ([@b2]; [@b19]). Obviously, BP self-measurement is only practicable if the devices are accurate, user-friendly, and relatively inexpensive. Particular attention must be paid to ensure the accuracy of the used devices ([@b20]). Ideally, recommended devices should have been submitted to independent clinical validation procedures. During recent years, various automated devices for self-measurement of BP have been fabricated, but only some have been validated ([@b20], [@b21]; [@b10]; [@b16]; [@b6]; [@b5]; [@b17]; [@b15]; [@b32]; [@b8]; [@b7]; [@b12]; [@b26]; [@b9]; [@b1]; [@b18]; [@b30]; [@b27]; [@b29]) according to recognized protocols specifically designed for this purpose, such as the British Hypertension Society (BHS) protocol ([@b22], [@b23]), the Association for the Advancement of Medical Instrumentation (AAMI) protocol ([@b3], [@b4]) and the most recent International Protocol ([@b24]) published by the European Society of Hypertension (ESH). In this study, 4 devices for self-measurement of BP were validated according to the ESH protocol in 4 separate studies ([@b24]).

Methods
=======

Devices
-------

### Omron M1 plus (HEM-4011C-E)

The Omron M1 Plus device records brachial BP oscillometrically with a BP measurement range of 0--299 mmHg and heart rate range of 40--180 beats/min. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate are displayed on a liquid crystal digital (LCD) read-out. Inflation is manual by pumping the inflation bulb. Measurement starts automatically after having stopped inflating the arm cuff. Deflation is made by pressing the air release button to release the air in the arm cuff; this is an automatic pressure release valve. Standard cuff type adult for an arm circumferences ranging from 220 to 320 mm is provided.

### Omron M6 comfort (HEM-7000-E)

The Omron M6 Comfort (HEM 7000-E) device records brachial BP oscillometrically with a BP measurement range of 0--299 mmHg and heart rate range of 40--180 beats/min. SBP, DBP, and heart rate are displayed on an LCD read-out. The inflation is performed using a fuzzy-logic electric pumping system and the deflation by an automatic pressure release valve. Standard cuff type adult for an arm circumference ranging from 220 to 420 mm is provided, which fits both standard and large arm circumferences (cuff dimensions: 152 × 600 mm; weight: 240 g).

### Spengler KP7500D

The Spengler KP7500D device records brachial BP oscillometrically with a BP measurement range of 20--300 mmHg and heart rate range of 40--200 beats/min. SBP, DBP, and heart rate are displayed on an LCD read-out. Inflation is automatic by a micro rolling pump. Measurement starts automatically after having pressed and released the power button. Deflation is automatic by an automatic pressure release valve to release the air in the arm cuff. Standard adult cuff type for an arm circumference ranging from 220 to 320 mm is provided.

### Microlife BP A100 plus

The Microlife BP A100 Plus device records brachial BP oscillometrically with a BP measurement range of 30--280 mmHg and heart rate range of 40--200 beats/min. SBP, DBP, and heart rate are displayed on an LCD read-out. Measurement starts automatically; deflation is also automatic by a constant air release solenoid valve. Standard adult cuff type for an arm circumference ranging from 220 to 320 mm is provided. Two other cuffs, small (arm circumference 170--220 mm), and extra large cuffs (320--420 mm) are optional.

### Device validation

Each device was validated separately in specific populations and at different times. Therefore, each patient participated in only one study device validation. The devices were validated according to the ESH protocol. For each study, the manufacturer was asked to loan 2 or 3 devices with 2 different size cuffs (medium and large).

Factors affecting accuracy of measurements were described by the manufacturers according to the requirements of the International Protocol and were taken into consideration during the validation procedure.

The validation team consisted of 3 persons experienced in BP measurement who also had received training based on a CD-ROM ([@b13]) specifically developed by the French Society of Hypertension for the certification of observers involved in clinical studies. Two of the three observers simultaneously measured BP using a standard mercury sphygmomanometer, the components of which had been carefully checked before the study, and the third observer was the supervisor who checked the values obtained by the two observers and measured the BP by the tested device.

Analysis according to the International Protocol consisted of 2 phases. In the first phase, 15 subjects (45 BP measurements) were recruited; devices passing this primary phase proceeded to the second phase, for which a further 18 subjects (54 BP measurements) were recruited. All the devices were validated at the same center, by the same observers but at different times and in different populations.

Subject selection
-----------------

For each study, selection of subjects was done according to the recommendations of the International Protocol ([Table 1](#tbl1){ref-type="table"}). Four different populations were used in these 4 validation procedures. Arm circumferences were measured in each patient to ensure the use of an adequate cuff size; arm circumferences were distributed by chance according to the ESH protocol. In order to fulfill the BP criteria ranges and to optimize recruitment, it is recommended that subjects for the high diastolic and low systolic groups should be recruited first, then those with high systolic and low diastolic, and finally the remaining gaps should be filled. Thirty-three subjects with both SBP and DBP measurements corresponding to the requested BP ranges were selected to validate each of the four devices.

###### 

BP ranges for entry BP

           SBP (mmHg)   DBP (mmHg)
  -------- ------------ ------------
  Low      90--129      40--79
  Medium   130--160     80--100
  High     161--180     101--130

**Abbreviations:** SBP, systolic blood pressure; DBP, diastolic blood pressure.

For the primary phase, 5 of the 15 subjects should have an SBP in each of the ranges. Similarly, 5 of the 15 subjects should have a DBP in each of the ranges. For the second phase, 11 of the 33 subjects (including the first 15 subjects) should have SBP and DBP in each of the ranges. There are 3 ranges for SBP and 3 for DBP, with 11 subjects in each range to provide 99 pairs of measurements. Final analysis is performed on the 99 paired measurements.

Procedure
---------

### BP measurements by the observers

The subjects were seated in a quiet room and BP measurements started after a 10-minute rest period. Arm circumference was measured and brachial BP cuff size was adapted to the circumference. All measurements were made on the left arm at the heart level. BP was measured simultaneously (Y tube) with 2 calibrated mercury sphygmomanometers by the two observers alternately with the device undergoing validation. The observers were blinded to each other's readings.

Measurements were carried out in the following sequence for all 4 validation procedures:

*BPA* Entry BP, observers 1 and 2 each with independent mercury standard sphygmomanometer. The mean values were used to categorize the subject into a low, medium, or high range separately for SBP and DBP ([Table 1](#tbl1){ref-type="table"}).

*BPB* Device detection BP, observer 3. This BP was measured to allow the tested device to determine the BP characteristics of the subject and was not included in the analysis.

1.  *BP1* Observers 1 and 2 with the mercury standard.

2.  *BP2* Supervisor with the tested device.

3.  *BP3* Observers 1 and 2 with the mercury standard.

4.  *BP4* Supervisor with the tested device.

5.  *BP5* Observers 1 and 2 with the mercury standard.

6.  *BP6* Supervisor with the tested device.

7.  *BP7* Observers 1 and 2 with the mercury standard.

Accuracy criteria
-----------------

The concept of the International Protocol is to classify the differences between the device tested and control measurements according to whether these differences lie within 5, 10, or 15 mmHg. Differences are always calculated by subtracting the tested observer measurement from the device measurement. Differences were classified separately in this way for both SBP and DBP.

Subject measurements
--------------------

For assessment of accuracy, only measurements BP1 to BP7 were used. The mean of each pair of observer measurements was calculated; this was denoted as observer measurement BP1, BP3, BP5, or BP7. Each device measurement was flanked by two of these observer measurements, and one of these was selected as the comparative measurement as follows:

1.  1- The differences between BP2-BP1, BP2-BP3, BP4-BP3, BP4-BP5, BP6-BP5, and BP6-BP7 were calculated.

2.  2- The absolute values of the differences were calculated.

3.  3- These were paired according to the device reading.

4.  4- If the values in a pair were unequal, the observer measurement corresponding to the smaller difference was used.

5.  5- If the values in a pair were equal, the first of the 2 observer measurements was used.

6.  When this had been completed, there were 3 device readings for SBP and 3 for DBP for each subject. Each of these 6 readings had a single corresponding observer measurement, a difference between the two and a band for that difference categorized as follows: (0--5 mmHg, 6--10 mmHg, 11--15 mmHg, \>15 mmHg).

Assessment
----------

After all BP ranges have been filled ([Table 1](#tbl1){ref-type="table"}), there were 45 sets of measurements for both SBP and DBP for the first phase (15 subjects) and 99 sets for the second phase (33 subjects).

The number of differences in each zone was calculated and compared to the number required by the International Protocol and a continue/fail grade for first phase and pass/fail grade for second phase (phase 2.1) was determined. Also for the second phase, the number of measurements falling within 5 mmHg was determined for each of the 33 subjects and a pass/fail recommendation was determined according to the protocol (phase 2.2). For this phase at least 22 of the 33 subjects should have at least 2 of their 3 comparisons lying within 5 mmHg. And at most 3 of the 33 subjects can have all three of their comparison over 5 mmHg apart. To pass the validation and to be recommended for clinical use, a device must pass both phase 2.1 and phase 2.2. If it does not, it fails and is not recommended for clinical use.

Results
=======

Different populations were used in each of the validation procedures. The number of subjects screened for each device's study was: 43 pre-included subjects for the Omron M1 Plus, 52 for the Omron M6 Comfort, 46 for the Spengler KP7500 D, and 47 for the Microlife BP A100 Plus.

Omron M1 plus (HEM-4011C-E)
---------------------------

In the Omron M1 Plus study, mean age of the 33 subjects included was 58 ± 13 (21 men and 12 women), the arm circumference was 28 ± 4 (range: 19--38), and 26 standard cuffs, 6 large cuffs, and 1 small cuff were used ([Table 2](#tbl2){ref-type="table"}). The BP difference between the two observers was 0.95 ± 1.4 mmHg and 0.08 ± 0.84 mmHg for SBP and DBP respectively. The mean values of 99 measurements for SBP and DBP were respectively 136.5 ± 20.9/89.6 ± 16.4 mmHg with the Omron M1 Plus (HEM-4011C-E) device and 137.9 ± 22.1/90 ± 16 mmHg with the standard mercury sphygmomanometer. The mean and standard deviation of the difference between the device and the observers were −1.4 ± 5.5 and −0.4 ± 4.8 mmHg for SBP and DBP respectively.

###### 

Age, arm circumference distribution, and BP values for all four devices populations

                                Omron M1 Plus              Omron M6 Comfort           Spengler KP7500D         Microlife BP A100 Plus
  ----------------------------- -------------------------- -------------------------- ------------------------ --------------------------
  Age (years)                   58 ± 13                    52 ± 15                    59 ± 13                  57 ± 13
  Arm circ. distribution (cm)   28 ± 4                     29 ± 4                     30 ± 4                   29 ± 4
  Arm circ. range (cm)          19--38                     19--34                     23--40                   24--38
  BP (SBP/DBP) (mmHg)           136.5 ± 20.9/89.6 ± 16.4   133.8 ± 24.2/85.2 ± 13.9   138 ± 20.2/83.6 ± 17.0   141.9 ± 24.5/84.5 ± 16.4

**Abbreviations:** SBP, systolic blood pressure; DBP, diastolic blood pressure.

In total, 45 measurements (3 measurements × 15 subjects) were available for analysis in the first phase of the validation process, and 99 (3 measurements × 33 subjects) in the second phase. The number of measurements differing from the mercury sphygmomanometer standard by 5, 10, and 15 mmHg or less are shown in [Table 3](#tbl3){ref-type="table"}. These results are in accordance with the requested criteria of the International Protocol for the primary and secondary phases. Thus the Omron M1 Plus device fulfills the validation criteria of the International Protocol.

###### 

Results of the OMRON M1 Plus (HEM-4011C-E) device

  Phase 1                  ≤5 mmHg        ≤10 mmHg       ≤15 mmHg   Recomm.                 
  --------------- -------- -------------- -------------- ---------- ---------- ------------ -----
  Required        One of   25             35             40                                 
  Achieved        SBP      41             44             45         Continue                
  DBP             39       44             45             Continue                           
  **Phase 2.1**            ≤5 mmHg        ≤10 mmHg       ≤15 mmHg   Recomm.    Mean diff.   SD
                                                                                            
  Required        Two of   65             80             95                                 
  All of          60       75             90                                                
  Achieved        SBP      83             97             99         Pass       −1.4         5.5
  DBP             80       93             98             Pass       −0.4       4.8          
  **Phase 2.2**            2/3 ≤ 5 mmHg   0/3 ≤ 5 mmHg              Recomm.                 
                                                                                            
  Required                 ≥22            ≤3                                                
  Achieved        SBP      29             0                         Pass                    
  DBP             27       1                             Pass                               

**Abbreviations:** SBP, systolic blood pressure; DBP, diastolic blood pressure; Recomm., recommendation; Mean diff., mean difference (mmHg); SD, standard deviation (mmHg).

The difference between the device readings and the mean BP of the device and the two observers for all 99 points for SBP and DBP are shown in [Figure 1a](#fig1){ref-type="fig"} and [Figure 2a](#fig2){ref-type="fig"} respectively.

###### 

Plots for systolic blood pressure (SBP) difference between the test device readings and the mean of the two observer readings in 33 participants (n = 99) versus the mean of the devices and the mercury sphygmomanometer readings: (**a**) Omron M1 Plus (HEM 4011C-E), (**b**) Omron M6 Comfort (HEM-7000-E), (**c**) Spengler KP7500D, (**d**) Microlife BP A100 Plus.
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###### 

Plots for diastolic blood pressure (DBP) difference between the test device readings and the mean of the two observer readings in 33 participants (n = 99) versus the mean of the devices and the mercury sphygmomanometer readings: (**a**) Omron M1 Plus (HEM 4011C-E), (**b**) Omron M6 Comfort (HEM-7000-E), (**c**) Spengler KP7500D, (**d**) Microlife BP A100 Plus.
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Omron M6 comfort (HEM-7000-E)
-----------------------------

In the Omron M6 Comfort (HEM-7000-E) study, mean age of the 33 subjects included was 52 ± 15 (19 men and 14 women), the arm circumference was 29 ± 4 (range: 19--34), so the standard cuff was used for all subjects ([Table 2](#tbl2){ref-type="table"}). The difference between the two observers was 0.36 ± 1.88 mmHg and 0.34 ± 1.14 mmHg for SBP and DBP respectively. The mean values of 99 measurements for SBP and DBP were respectively 133.8 ± 24.2/85.2 ± 13.9 mmHg with the Omron M6 Comfort device and 135.9 ± 22.7/85.2 ± 13.8 mmHg with the standard mercury sphygmomanometer. The mean and standard deviation of the difference between the device and the observers were −2.13 ± 7.37 and 0.09 ± 4.91 mmHg for SBP and DBP respectively.

In total, 45 measurements (3 measurements × 15 subjects) were available for analysis in the first phase of the validation process, and 99 (3 measurements × 33 subjects) in the second phase. The number of measurements differing from the mercury standard by 5, 10, and 15 mmHg or less are shown in [Table 4](#tbl4){ref-type="table"}. These results are in accordance with the requested criteria of the International Protocol for the primary and secondary phases. Thus the Omron M6 Comfort device fulfills the validation criteria of the International Protocol.

###### 

Results of the OMRON M6 Comfort (HEM 7000-E) device

  Phase 1                  ≤5 mmHg        ≤10 mmHg       ≤15 mmHg   Recomm.                 
  --------------- -------- -------------- -------------- ---------- ---------- ------------ -----
  Required        One of   25             35             40                                 
  Achieved        SBP      32             37             40         Continue                
  DBP             38       43             45             Continue                           
  **Phase 2.1**            ≤5 mmHg        ≤10 mmHg       ≤15 mmHg   Recomm.    Mean diff.   SD
                                                                                            
  Required        Two of   65             80             95                                 
  All of          60       75             90                                                
  Achieved        SBP      67             81             90         Pass       −2.1         7.4
  DBP             73       93             99             Pass       0.1        4.9          
  **Phase 2.2**            2/3 ≤ 5 mmHg   0/3 ≤ 5 mmHg              Recomm.                 
                                                                                            
  Required                 ≥22            ≤3                                                
  Achieved        SBP      25             3                         Pass                    
  DBP             25       3                             Pass                               

**Abbreviations:** SBP, systolic blood pressure; DBP, diastolic blood pressure; Recomm., recommendation; Mean diff., mean difference (mmHg); SD, standard deviation (mmHg).

The difference between the device readings and the mean BP of the device and the two observers for all 99 points for SBP and DBP are shown in [Figure 1b](#fig1){ref-type="fig"} and [Figure 2b](#fig2){ref-type="fig"} respectively.

Spengler KP7500D
----------------

In the Spengler KP7500D study, mean age of the 33 subjects included was 59 ± 13 (21 men and 12 women), the arm circumference was 30 ± 4 (range: 23--40), and 29 standard cuffs and 4 large cuffs were used ([Table 2](#tbl2){ref-type="table"}). The difference between the two observers was 0.01 ± 2.01 mmHg and 0.1 ± 1.6 mmHg for SBP and DBP respectively. The mean values of 99 measurements for SBP and DBP were respectively 138 ± 20.2/83.6 ± 17.0 mmHg with the Spengler KP7500D device and 139.4 ± 21.9/83.7 ± 16.3 mmHg with the standard mercury sphygmomanometer. The mean and standard deviation of the difference between the device and the observers were −1.4 ± 8.6 and −0.1 ± 3.5 mmHg for SBP and DBP respectively.

In total, 45 measurements (3 measurements × 15 subjects) were available for analysis in the first phase of the validation process, and 99 (3 measurements × 33 subjects) in the second phase. The number of measurements differing from the mercury standard by 5, 10, and 15 mmHg or less are shown in [Table 5](#tbl5){ref-type="table"}. These results are in accordance with the requested criteria of the International Protocol for the primary and secondary phases. Thus the Spengler KP7500D device fulfills the validation criteria of the International Protocol.

###### 

Results of the Spengler KP7500D device

  Phase 1                  ≤5 mmHg        ≤10 mmHg       ≤15 mmHg   Recomm.                 
  --------------- -------- -------------- -------------- ---------- ---------- ------------ -----
  Required        One of   25             35             40                                 
  Achieved        SBP      40             40             42         Continue                
  DBP             42       43             44             Continue                           
  **Phase 2.1**            ≤5 mmHg        ≤10 mmHg       ≤15 mmHg   Recomm.    Mean diff.   SD
                                                                                            
  Required        Two of   65             80             95                                 
  All of          60       75             90                                                
  Achieved        SBP      86             92             96         Pass       −1.4         8.6
  DBP             93       96             98             Pass       −0.1       3.5          
  **Phase 2.2**            2/3 ≤ 5 mmHg   0/3 ≤ 5 mmHg              Recomm.                 
                                                                                            
  Required                 ≥22            ≤3                                                
  Achieved        SBP      29             1                         Pass                    
  DBP             31       1                             Pass                               

**Abbreviations:** SBP, systolic blood pressure; DBP, diastolic blood pressure; Recomm., recommendation; Mean diff., mean difference (mmHg); SD, standard deviation (mmHg).

The difference between the device readings and the mean BP of the device and the two observers for all 99 points for SBP and DBP are shown in [Figure 1c](#fig1){ref-type="fig"} and [Figure 2c](#fig2){ref-type="fig"} respectively.

Microlife BP A100 plus
----------------------

In the Microlife BP A100 Plus study, mean age of the 33 subjects included was 57 ± 13 (23 men and 10 women), the arm circumference was 29 ± 4 (range: 24--38), and 26 standard cuffs and 7 large cuffs were used ([Table 2](#tbl2){ref-type="table"}). The difference between the two observers was 0.067 ± 1.7 mmHg and 0.12 ± 0.98 mmHg for SBP and DBP respectively. The mean values of 99 measurements for SBP and DBP were respectively 141.9 ± 24.5/84.5 ± 16.4 mmHg with the Microlife BP A100 Plus device and 140.3 ± 24.7/83.9 ± 17.35 mmHg with the standard mercury sphygmomanometer. The mean and standard deviation of the difference between the device and the observers were 1.6 ± 4.2 and 0.54 ± 2.8 mmHg for SBP and DBP respectively.

In total, 45 measurements (3 measurements × 15 subjects) were available for analysis in the first phase of the validation process, and 99 (3 measurements × 33 subjects) in the second phase. The number of measurements differing from the mercury standard by 5, 10, and 15 mmHg or less, are shown in [Table 6](#tbl6){ref-type="table"}. These results are in accordance with the requested criteria of the International Protocol for the primary and secondary phases. Thus the Microlife BP A100 Plus device fulfills the validation criteria of the International Protocol.

###### 

Results of the Microlife BP A100 Plus device

  Phase 1                  ≤5 mmHg        ≤10 mmHg        ≤15 mmHg   Recomm.                 
  --------------- -------- -------------- --------------- ---------- ---------- ------------ -----
  Required        One of   25             35              40                                 
  Achieved        SBP      40             45              45         Continue                
  DBP             42       45             45              Continue                           
  **Phase 2.1**            ≤5 mmHg        ≤10 mmHg        ≤15 mmHg   Recomm.    Mean diff.   SD
                                                                                             
  Required        Two of   65             80              95                                 
  All of          60       75             90                                                 
  Achieved        SBP      84             96              98         Pass       1.6          4.2
  DBP             91       99             99              Pass       0.54       2.8          
  **Phase 2.2**            2/3 ≤ 5 mmHg   0/3 \> 5 mmHg              Recomm.                 
                                                                                             
  Required                 ≥22            ≤3                                                 
  Achieved        SBP      30             2                          Pass                    
  DBP             33       0                              Pass                               

**Abbreviations:** SBP, systolic blood pressure; DBP, diastolic blood pressure; Recomm., recommendation; Mean diff., mean difference (mmHg); SD, standard deviation (mmHg).

The difference between the device readings and the mean BP of the device and the two observers for all 99 points for SBP and DBP are shown in [Figure 1d](#fig1){ref-type="fig"} and [Figure 2d](#fig2){ref-type="fig"} respectively.

Discussion
==========

The tested devices, Omron M1 Plus (HEM-4011C-E), Omron M6 Comfort (HEM-7000-E), Spengler KP7500D, and Microlife BP A100 Plus, fulfilled the validation criteria of the International Protocol for SBP and for DBP. The International Protocol recommendations ([@b24]) have been published by the Working Group on Blood Pressure Monitoring of the ESH with the aim of simplifying the two main available guidelines, the BHS ([@b22], [@b23]) and AAMI ([@b3], [@b4]) protocols without sacrificing their integrity. These two validation protocols have many similarities but experience has demonstrated that the conditions they recommend are sometimes extremely difficult to fulfill especially because of the large number of subjects who have to be recruited and the ranges of BP required. It has been demonstrated by the ESH Working Group that validation studies can be performed in such a way as to satisfy the criteria of the much more complicated earlier protocols ([@b24]). The main advantage of the International Protocol is that it requires fewer subjects, 33 instead of 85 with the two other protocols.

Our experience with the validation of these devices shows that the recruitment of subjects having low SBP (90--129 mmHg) and especially high DBP (101--130 mmHg) is the major factor that extends the time required for the validation, although the International Protocol recommends that recruitment of subjects should commence by targeting those likely to have pressures in the low-systolic and high-diastolic ranges so that it will be easy to complete the recruitment with the remaining ranges.

Another point that remains a limit of the present study is that the results are based on only one device and the validation was done in only one center; however the International Protocol ([@b24]) does not specify the number of devices to be tested or the number of study sites recommended to enhance the heterogeneity of the study population. The AAMI protocol ([@b3], [@b4]) recommends more than one study site without specifying the number and without noting the number of devices used for the validation. On the other hand, the BHS protocol ([@b22], [@b23]) does not specify performing the validation in more than one site but recommends assessing the capability of a number of devices of the tested model to give consistent measurements. If substantial differences between instruments of the same device occur, further device validation is not appropriate. In this regard, [@b27] reported recently similar results for the Microlife BP A100 Plus device.

It is important to mention here that these validation studies were performed in the general population and that the observed results cannot be extrapolated to specific populations such as the elderly, the obese, and children. Specific validation studies are needed in specific populations.

This study shows that increased error at extremes of BP occurs in virtually all non-invasive devices, but the degree of error varies ([@b32]; [@b8]; [@b11]). It is, however, also important to recognize that this usually bears little clinical relevance since therapeutic decisions would not significantly differ ([@b32]).

In conclusion, the tested devices, Omron M1 Plus (HEM-4011C-E), Omron M6 Comfort (HEM-7000-E), Spengler KP7500D, and Microlife BP A100 Plus have passed the validation criteria of the International Protocol for validation of BP measuring devices.
